Ranibizumab-pegaptanib therapy for idiopathic choroidal neovascularization: report of a case.
Idiopathic choroidal neovascularization is a rather uncommon condition in children and young adults. While some cases resolve spontaneously, in this case visual acuity deteriorated from 20/25 to 20/80 in the affected eye of a 20-year-old college student. After weighing numerous treatment options, she was treated with an intravitreal injection of Ranibizumab (Lucentis) which induced an involution of the membrane over one month's time. Vision recovered to 20/20-1. A follow-up injection with Pegaptanib sodium (Macugen) was administered to promote further involution of the membrane. Vision remained stable over the next four months with no recurrence of the membrane.
Friberg
Thomas R
TR
Department of Ophthalmology, University of Pittsburgh, School of Medicine, UPMC Eye Center, Pittsburgh, PA 15213, USA. friberg@pitt.edu
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000008:administration & dosage / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D005260:Female; D005654:Fundus Oculi; D006801:Humans; D007267:Injections; D000069579:Ranibizumab; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; C495058:pegaptanib; D000069579:Ranibizumab